You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
McKinsey
Colorcon

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,759,234

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,759,234
Title: Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
Abstract:The present invention provides therapeutic compositions and methods for treating disease conditions in humans associated with an antigen specific immune response by the human to an antigen such as a protein antigen (i.e. allergy and autoimmune diseases). Therapeutic compositions of the invention are reproducible preparations which are suitable for human therapy. Compositions of the invention comprise at least one isolated peptide having a defined sequence of amino acid residues and the composition is capable of down regulating an antigen specific immune response to an offending antigen in a population of humans subject to the antigen specific immune response. Compositions and methods of the invention may be used to treat sensitivity to protein allergens in humans and may also be used to treat autoimmune disease such as rheumatoid arthritis, diabetes, myasthenia gravis, Grave\'s disease, Good Pasture\'s syndrome, thyroiditis and multiple sclerosis.
Inventor(s): Gefter; Malcolm L. (Lincoln, MA), Shaked; Ze\'ev (Berkeley, CA), Morville; Malcolm (Shrewsbury, MA)
Assignee: Immulogic Pharmaceutical Corporation (Waltham, MA)
Application Number:08/300,510
Patent Claims:1. A method of treating allergy in humans comprising administering to a human at least one therapeutic composition in an amount sufficient to down regulate a protein allergen specific immune response in the human, wherein the therapeutic composition comprises at least one isolated peptide having a defined sequence of amino acid residues, said peptide comprising at least about 20% of the T cell epitopes of the protein allergen, said peptide being reproducible and not being conjugated to any other molecule, said peptide having a mean T cell stimulation index of at least about 3.5determined in an in vitro T cell proliferation assay with T cell obtained from a population of humans sensitive to said allergen, and said peptide having a positivity index of at least 150 as determined in an in vitro T cell proliferation assay with T cell obtained from a population of humans sensitive to said allergen, wherein the composition is first administered at three to six dosages of said composition once a week for three to six weeks.

2. The method of claim 1 further comprising a second administration of said composition at intervals of between about three months and one year after said first administration.

3. The method of claim 1, wherein the peptide comprises 50 amino acid residues or less.

4. The method as in any one of claims 1 or 3, further comprising the step of increasing the dosage with each subsequent additional dosage of said composition.

5. The method as in any one of claims 1 or 3, wherein treatment results in a statistically significant improvement in symptoms caused by the human's immune response to the protein allergen.

6. The method as in any one of claims 1 or 3, wherein the peptide is modified by at least one amino acid substitution, addition or deletion, said peptide comprising a T cell epitope recognized by a T cell receptor specific for the protein allergen.

7. The method as in any one of claims 1 or 3, wherein the peptide is purified to at least 90% purity.

8. The method of claim 7, wherein the peptide is purified to at least 95% purity.

9. The method of claim 8, wherein the peptide is purified to at least 97% purity.

10. The method as in any one of claims 1 or 3, wherein the peptide is at least about 12 amino acid residues in length.

11. The method as in any one of claims 1 or 3, wherein the at least one peptide comprises at least two peptides.

12. The method as in any one of claims 1 or 3, wherein the protein allergen is selected from the group consisting of: a protein allergen of the genus Dermatophagoides; a protein allergen of the genus Felis; a protein allergen of the genus Ambrosia; a protein allergen of the genus Lolium; a protein allergen of the genus Cryptomeria; a protein allergen of the genus Alternaria; a protein allergen of the genus Alder; a protein allergen of the genus Betula; a protein allergen of the genus Quercus; a protein allergen of the genus Olea; a protein allergen of the genus Artemisia; a protein allergen of the genus Plantago; a protein allergen of the genus Parietaria; a protein allergen of the genus Canine; a protein allergen of the genus Blattella; a protein allergen of the genus Apis; a protein allergen of the genus Cupressus; a protein allergen of the genus Juniperus; a protein allergen of the genus Thuya; a protein allergen of the genus Chamaecyparis; a protein allergen of the genus Periplaneta; a protein allergen of the genus Agropyron; a protein allergen of the genus Secale; a protein allergen of the genus Triticum; a protein allergen of the genus Dactylis; a protein allergen of the genus Festuca; a protein allergen of the genus Poa; a protein allergen of the genus Avena; a protein allergen of the genus Holcus; a protein allergen of the genus Anthoxanthum; a protein allergen of the genus Arrhenatherum; a protein allergen of the genus Agrostis; a protein allergen of the genus Phleum; a protein allergen of the genus Phalaris; a protein allergen of the genus Paspalum; and a protein allergen of the genus Sorghum.

13. The method of claim 12, wherein the protein allergen is selected from the group consisting of; Der p I; Der p II; Der p III; Der p VII; Der f I; Der f II; Der f III; Der f VII; Fel d I; Amb a I.1; Amb a I.2; Amb a I.3; Amb a I.4; Amb a II; Lol p I, Lol p II; Lol p III; Lol p IV; Lol p IX (Lol p V or Lol p Ib); Cry j I; Cry j II; Can fI; Can f II; Jun s I; Jun v I; Dac g I; Poa p I; Phl p I; and Sor h I.

14. The method as in any one of claims 1 or 3, wherein the composition further comprises a pharmaceutically acceptable carrier.

15. The method of claim 14, wherein the pharmaceutically acceptable carrier comprises at least one excipient selected from the group consisting of sterile water, sodium phosphate, mannitol, sorbitol, sodium chloride, and any combination thereof.

16. The method as in any one of claims 1 or 3, wherein the composition soluble in an aqueous solution at a physiologically acceptable pH.

17. The method as in any one of claims 1 or 3, wherein said administering comprises a route of administration selected from the group consisting of oral, intravenous, sublingual, transdermal, inhalation, subcutaneous and rectal.

18. The method of claim 17, wherein said administering comprises subcutaneous administration of said composition.

19. The method as in any one of claims 1 or 3, wherein said composition is administered without adjuvant.

20. A method of treating allergy in humans comprising administering to a human at least one therapeutic composition in an amount sufficient to down regulate a protein allergen specific immune response in the human, wherein the therapeutic composition comprises at least one isolated peptide having a defined sequence of amino acid residues, said peptide comprising at least about 20% of the T cell epitopes of the protein allergen, said peptide being reproducible and not being conjugated to any other molecule, said peptide having a mean T cell stimulation index of at least about 3.5 determined in an in vitro T cell proliferation assay with T cells obtained from a population of humans sensitive to said allergen, and said peptide having a positivity index of at least 150 as determined in an in vitro T cell proliferation assay with T cells obtained from a population of humans sensitive to said allergen, comprising the step of decreasing the dosage with each subsequent additional dosage of said composition.

Details for Patent 6,759,234

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial Immulogic Pharmaceutical Corporation (Waltham, MA) 2039-09-23 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial Immulogic Pharmaceutical Corporation (Waltham, MA) 2039-09-23 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.